Tags

Type your tag names separated by a space and hit enter

New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.
Expert Opin Pharmacother. 2008 Apr; 9(5):795-811.EO

Abstract

BACKGROUND

Hyperparathyroidism (HPT), characterised by increased parathyroid hormone (PTH) secretion and parathyroid hyperplasia, can be caused by physiologic defects in the parathyroid gland (primary HPT [PHPT]) or as a consequence of declining renal function (secondary HPT [SHPT]).

OBJECTIVE

To review the safety and efficacy of cinacalcet in the treatment of SHPT and PHPT.

METHODS

Studies indexed in NLM/PubMed investigating the safety, efficacy, and pharmacokinetics of cinacalcet for PHPT and SHPT and supporting preclinical evidence.

RESULTS/CONCLUSION

Recent evidence has demonstrated the efficacy of the calcimimetic cinacalcet in the treatment of PHPT and SHPT. Compared with traditional therapies such as vitamin D sterols and phosphate binders, cinacalcet treatment can allow an increased proportion of patients with SHPT to improve Kidney Disease Outcomes Quality Initiative (KDOQI) Bone Metabolism and Disease laboratory parameter target attainment. Recent evidence suggests that improvements in these biochemical parameters with cinacalcet can translate into improved morbidity and mortality. Cinacalcet lowers PTH and calcium in patients following renal transplantation, and also normalises serum calcium in patients with PHPT. Ongoing studies are focusing and future studies are likely to focus on the effect of cinacalcet on clinical outcomes and on novel strategies for the integration of cinacalcet with traditional therapies to improve serum PTH and mineral metabolism control.

Authors+Show Affiliations

Servicio de Nefrologia, Hospital Universitario Valdecilla, Avda Valdecilla s/n, E-39008 Santander, Spain. martinal@unican.es

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18345956

Citation

de Francisco, Angel L M.. "New Strategies for the Treatment of Hyperparathyroidism Incorporating Calcimimetics." Expert Opinion On Pharmacotherapy, vol. 9, no. 5, 2008, pp. 795-811.
de Francisco AL. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics. Expert Opin Pharmacother. 2008;9(5):795-811.
de Francisco, A. L. (2008). New strategies for the treatment of hyperparathyroidism incorporating calcimimetics. Expert Opinion On Pharmacotherapy, 9(5), 795-811. https://doi.org/10.1517/14656566.9.5.795
de Francisco AL. New Strategies for the Treatment of Hyperparathyroidism Incorporating Calcimimetics. Expert Opin Pharmacother. 2008;9(5):795-811. PubMed PMID: 18345956.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - New strategies for the treatment of hyperparathyroidism incorporating calcimimetics. A1 - de Francisco,Angel L M, PY - 2008/3/19/pubmed PY - 2008/4/11/medline PY - 2008/3/19/entrez SP - 795 EP - 811 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 9 IS - 5 N2 - BACKGROUND: Hyperparathyroidism (HPT), characterised by increased parathyroid hormone (PTH) secretion and parathyroid hyperplasia, can be caused by physiologic defects in the parathyroid gland (primary HPT [PHPT]) or as a consequence of declining renal function (secondary HPT [SHPT]). OBJECTIVE: To review the safety and efficacy of cinacalcet in the treatment of SHPT and PHPT. METHODS: Studies indexed in NLM/PubMed investigating the safety, efficacy, and pharmacokinetics of cinacalcet for PHPT and SHPT and supporting preclinical evidence. RESULTS/CONCLUSION: Recent evidence has demonstrated the efficacy of the calcimimetic cinacalcet in the treatment of PHPT and SHPT. Compared with traditional therapies such as vitamin D sterols and phosphate binders, cinacalcet treatment can allow an increased proportion of patients with SHPT to improve Kidney Disease Outcomes Quality Initiative (KDOQI) Bone Metabolism and Disease laboratory parameter target attainment. Recent evidence suggests that improvements in these biochemical parameters with cinacalcet can translate into improved morbidity and mortality. Cinacalcet lowers PTH and calcium in patients following renal transplantation, and also normalises serum calcium in patients with PHPT. Ongoing studies are focusing and future studies are likely to focus on the effect of cinacalcet on clinical outcomes and on novel strategies for the integration of cinacalcet with traditional therapies to improve serum PTH and mineral metabolism control. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/18345956/New_strategies_for_the_treatment_of_hyperparathyroidism_incorporating_calcimimetics_ L2 - http://www.tandfonline.com/doi/full/10.1517/14656566.9.5.795 DB - PRIME DP - Unbound Medicine ER -